XENETIC BIOSCIENCES, INC. Stock Split Ratio
XENETIC BIOSCIENCES, INC. (XBIO) reported Stock Split Ratio of 8.33% for the 6-month period ending 2019-06-25, per its 10-Q filed 2020-11-12.
Discontinued › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2020-11-12
- 2019-06-25: Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month 8.33%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month |
|---|---|
| 2019-06-25 | 8.33% 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |